{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:13:52Z","timestamp":1788509632757,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xphs.2026.104286","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:07:50Z","timestamp":1776294470000},"page":"104286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SMARCA2 PROTAC-dendrimer conjugates for the treatment of non-small cell lung cancer"],"prefix":"10.1016","volume":"115","author":[{"given":"Matthew","family":"O\u2019Brien Laramy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosliana","family":"Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summer Baker","family":"Dockrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Fan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"del Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-6283","authenticated-orcid":false,"given":"Robert L.","family":"Yauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ely","family":"Cosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1852-5836","authenticated-orcid":false,"given":"Graham","family":"Heery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Chadwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9165-1540","authenticated-orcid":false,"given":"David","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hufton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.xphs.2026.104286_bib0001","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41573-023-00652-2","article-title":"Delivering on the promise of protein degraders","volume":"22","author":"O\u2019Brien Laramy","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xphs.2026.104286_bib0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) \u2014 past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.xphs.2026.104286_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100647","article-title":"Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs","volume":"296","author":"Alabi","year":"2021","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.xphs.2026.104286_bib0004","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"10.1016\/j.xphs.2026.104286_bib0005","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.4155\/fmc-2021-0033","article-title":"Perspectives on the development of first-in-class protein degraders","volume":"13","author":"Rambacher","year":"2021","journal-title":"Fut Med Chem"},{"issue":"2","key":"10.1016\/j.xphs.2026.104286_bib0006","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J Med Chem"},{"issue":"13","key":"10.1016\/j.xphs.2026.104286_bib0007","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019 chemical space: recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"10","key":"10.1016\/j.xphs.2026.104286_bib0008","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1039\/C9MD00272C","article-title":"Developing degraders: principles and perspectives on design and chemical space","volume":"10","author":"Maple","year":"2019","journal-title":"Medchemcomm"},{"issue":"12","key":"10.1016\/j.xphs.2026.104286_bib0009","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1021\/acs.jmedchem.3c00740","article-title":"Physicochemical property determinants of oral absorption for PROTAC protein degraders","volume":"66","author":"Hornberger","year":"2023","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.xphs.2026.104286_bib0010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.drudis.2020.03.012","article-title":"Fundamental aspects of DMPK optimization of targeted protein degraders","volume":"25","author":"Cantrill","year":"2020","journal-title":"Drug Discov Today"},{"issue":"10","key":"10.1016\/j.xphs.2026.104286_bib0011","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","article-title":"Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective","volume":"25","author":"Pike","year":"2020","journal-title":"Drug Discov Today"},{"issue":"3","key":"10.1016\/j.xphs.2026.104286_bib0012","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4155\/fmc-2021-0223","article-title":"Challenges and opportunities for In vivo PROTAC delivery","volume":"14","author":"Benowitz","year":"2022","journal-title":"Fut Med Chem"},{"issue":"1","key":"10.1016\/j.xphs.2026.104286_bib0013","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/pharmaceutics15010156","article-title":"Solubility enhanced formulation approaches to overcome oral delivery obstacles of PROTACs","volume":"15","author":"P\u00f6stges","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2026.104286_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123725","article-title":"ASDs of PROTACs: spray-dried solid dispersions as enabling formulations","volume":"650","author":"Hofmann","year":"2024","journal-title":"Int J Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2026.104286_bib0015","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1039\/D2CS00141A","article-title":"Degrader-antibody conjugates","volume":"51","author":"Dragovich","year":"2022","journal-title":"Chem Soc Rev"},{"issue":"19","key":"10.1016\/j.xphs.2026.104286_bib0016","doi-asserted-by":"crossref","first-page":"9582","DOI":"10.1039\/D4CS00411F","article-title":"Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design","volume":"53","author":"Chen","year":"2024","journal-title":"Chem Soc Rev"},{"issue":"4","key":"10.1016\/j.xphs.2026.104286_bib0017","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/pharmaceutics17040501","article-title":"PROTAC delivery strategies for overcoming physicochemical properties and physiological barriers in targeted protein degradation","volume":"17","author":"Syahputra","year":"2025","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.xphs.2026.104286_bib0018","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/s41565-024-01754-7","article-title":"A translational framework to DELIVER nanomedicines to the clinic","volume":"19","author":"Joyce","year":"2024","journal-title":"Nat Nanotechnol"},{"issue":"4","key":"10.1016\/j.xphs.2026.104286_bib0019","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13543776.2024.2355258","article-title":"Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors \u2013 a review of patent literature from 2019\u2013June 2023","volume":"34","author":"Lee","year":"2024","journal-title":"Expert Opin Ther Pat"},{"issue":"1","key":"10.1016\/j.xphs.2026.104286_bib0020","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1038\/s41467-022-34562-5","article-title":"Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers","volume":"13","author":"Cantley","year":"2022","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.xphs.2026.104286_bib0021","doi-asserted-by":"crossref","first-page":"10761","DOI":"10.1021\/acs.jmedchem.3c00953","article-title":"Discovery of SMD-3040 as a potent and selective SMARCA2 PROTAC degrader with strong in vivo antitumor activity","volume":"66","author":"Yang","year":"2023","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.xphs.2026.104286_bib0022","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.jmedchem.3c01781","article-title":"PROTACs targeting BRM (SMARCA2) afford selective In vivo degradation over BRG1 (SMARCA4) and are active in BRG1 mutant xenograft tumor models","volume":"67","author":"Berlin","year":"2024","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.xphs.2026.104286_bib0023","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-25-2928","article-title":"A double-negative prostate cancer subtype is vulnerable to SWI\/SNF-targeting degrader molecules","volume":"86","author":"Thienger","year":"2026","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.xphs.2026.104286_bib0024","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1021\/acs.jmedchem.4c01904","article-title":"Discovery of SMD-3236: A potent, highly selective and efficacious SMARCA2 degrader for the treatment of SMARC4-deficient Human cancers","volume":"68","author":"Yang","year":"2025","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.xphs.2026.104286_bib0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s43856-024-00505-y","article-title":"Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs","volume":"4","author":"Zhang","year":"2024","journal-title":"Commun Med"},{"key":"10.1016\/j.xphs.2026.104286_bib0026","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.5c01600","article-title":"Conformation-dependent complexation interactions for SMARCA2 PROTAC and cyclodextrin","author":"O\u2019Brien Laramy","year":"2026","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2026.104286_bib0027","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2217\/nnm.11.67","article-title":"Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties","volume":"6","author":"Kaminskas","year":"2011","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.xphs.2026.104286_bib0028","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/mp7001208","article-title":"The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers","volume":"5","author":"Kaminskas","year":"2008","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104286_bib0029","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","article-title":"Design and optimisation of dendrimer-conjugated bcl-2\/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy","volume":"4","author":"Patterson","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.xphs.2026.104286_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122905","article-title":"In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate","volume":"637","author":"Sonzini","year":"2023","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2026.104286_bib0031","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.xphs.2022.11.005","article-title":"The Global characterisation of a drug-dendrimer conjugate - PEGylated poly-lysine dendrimer","volume":"112","author":"Akhtar","year":"2023","journal-title":"J Pharm Sci"},{"issue":"26","key":"10.1016\/j.xphs.2026.104286_bib0032","first-page":"2918","article-title":"Dendrimer-nanoparticle (DEP) delivery of topoisomerase I inhibitor, SN38 (DEP-SN38): safety, tolerability, and preliminary efficacy study in patients with advanced solid tumors","volume":"43","author":"Liu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.xphs.2026.104286_bib0033","doi-asserted-by":"crossref","first-page":"103211","DOI":"10.1016\/j.rechem.2026.103211","article-title":"Modulation of VHL binding affinity improves selectivity of PROTACs targeting BRM (SMARCA2) over BRG1 (SMARCA4)","volume":"24","author":"Berlin","year":"2026","journal-title":"Results Chem"},{"key":"10.1016\/j.xphs.2026.104286_bib0034","series-title":"Mixed-Effects Models in S and S-PLUS","author":"Pinheiro","year":"2000"},{"issue":"2","key":"10.1016\/j.xphs.2026.104286_bib0035","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia","volume":"89","author":"Tisdale","year":"2009","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.xphs.2026.104286_bib0036","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.xphs.2026.104286_bib0037","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41420-021-00505-0","article-title":"A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma","volume":"7","author":"Arulananda","year":"2021","journal-title":"Cell Death Discov"},{"issue":"5","key":"10.1016\/j.xphs.2026.104286_bib0038","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1021\/mp060032e","article-title":"Cationic poly-l-lysine dendrimers:\u2009 pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats","volume":"3","author":"Boyd","year":"2006","journal-title":"Mol Pharm"},{"issue":"16_suppl","key":"10.1016\/j.xphs.2026.104286_bib0039","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2024.42.16_suppl.3004","article-title":"Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1\/2 trial (P1\/2)","volume":"42","author":"Spicer","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.xphs.2026.104286_bib0040","series-title":"Positive DEP Docetaxel Phase 2 Results","author":"Starpharma","year":"2023"},{"issue":"3","key":"10.1016\/j.xphs.2026.104286_bib0041","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1021\/mp200522d","article-title":"Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models","volume":"9","author":"Kaminskas","year":"2012","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104286_bib0042","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2026.104286_bib0043","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:34:57Z","timestamp":1788507297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926001358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022354926001358"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104286","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SMARCA2 PROTAC-dendrimer conjugates for the treatment of non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104286"}}